271 related articles for article (PubMed ID: 37289729)
21. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
22. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim SA; Farber IM; Noraldeen SAM; Bansal P; Alsaab HO; Abdullaev B; Alkhafaji AT; Alawadi AH; Hamzah HF; Mohammed BA
Microvasc Res; 2024 Jul; 154():104691. PubMed ID: 38703993
[TBL] [Abstract][Full Text] [Related]
24. Combined anti-angiogenic and cytotoxic treatment of a solid tumour: in silico investigation of a xenograft animal model's digital twin.
Hadjicharalambous M; Ioannou E; Aristokleous N; Gazeli K; Anastassiou C; Vavourakis V
J Theor Biol; 2022 Nov; 553():111246. PubMed ID: 36007551
[TBL] [Abstract][Full Text] [Related]
25. Metabolic Symbiosis-Blocking Nano-Combination for Tumor Vascular Normalization Treatment.
Xiong H; Liu X; Xie Z; Zhu L; Lu H; Wang C; Yao J
Adv Healthc Mater; 2022 Sep; 11(17):e2102724. PubMed ID: 35708141
[TBL] [Abstract][Full Text] [Related]
26. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
27. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
Mander KA; Finnie JW
Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
[TBL] [Abstract][Full Text] [Related]
28. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
29. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
30. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
[TBL] [Abstract][Full Text] [Related]
31. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
32. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
33. Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.
Ruan L; Zhang S; Chen X; Liang W; Xie Q
Pathol Res Pract; 2022 Aug; 236():153956. PubMed ID: 35700578
[TBL] [Abstract][Full Text] [Related]
34. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
[TBL] [Abstract][Full Text] [Related]
36. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Mittal K; Ebos J; Rini B
Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295
[TBL] [Abstract][Full Text] [Related]
38. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
39. Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models.
Ledzewicz U; Schaettler H
Adv Exp Med Biol; 2016; 936():209-223. PubMed ID: 27739050
[TBL] [Abstract][Full Text] [Related]
40. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
